BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Deng R, Zheng H, Cai H, Li M, Shi Y, Ding S. Effects of helicobacter pylori on tumor microenvironment and immunotherapy responses. Front Immunol 2022;13:923477. [DOI: 10.3389/fimmu.2022.923477] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Kang Y, Li S. Nanomaterials: Breaking through the bottleneck of tumor immunotherapy. Int J Biol Macromol 2023;230:123159. [PMID: 36610572 DOI: 10.1016/j.ijbiomac.2023.123159] [Reference Citation Analysis]
2 Deng R, Zhang H, Li Y, Shi Y. Effect of Antacid Use on Immune Checkpoint Inhibitors in Advanced Solid Cancer Patients: A Systematic Review and Meta-analysis. J Immunother 2023;46:43-55. [PMID: 36301729 DOI: 10.1097/CJI.0000000000000442] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Muhammad JS, Manzoor S, Cui ZG, Khoder G. DNA Methylation-Mediated Overexpression of CXCL1 in Helicobacter pylori-Induced Gastric Cancer: In Silico- and In Vitro-Based Identification of a Potential Biomarker for Carcinogenesis. Int J Mol Sci 2023;24. [PMID: 36614235 DOI: 10.3390/ijms24010795] [Reference Citation Analysis]
4 Moehler M, Högner A, Wagner AD, Obermannova R, Alsina M, Thuss-Patience P, van Laarhoven H, Smyth E. Recent progress and current challenges of immunotherapy in advanced/metastatic esophagogastric adenocarcinoma. Eur J Cancer 2022;176:13-29. [PMID: 36183651 DOI: 10.1016/j.ejca.2022.08.023] [Reference Citation Analysis]